Research programme: cancer and pain therapeutics - leon nanodrugs

Drug Profile

Research programme: cancer and pain therapeutics - leon nanodrugs

Alternative Names: In 006; In 011; In 012

Latest Information Update: 12 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator leon-nanodrugs
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Pain

Most Recent Events

  • 12 Jan 2017 Research programme: Cancer and pain therapeutics - Leon nanodrugs is available for licensing as of 12 Jan 2017. http://leon-nanodrugs.com/services/pipeline/
  • 12 Jan 2017 Preclinical trials in Cancer in Germany (unspecified route)
  • 12 Jan 2017 Preclinical trials in Pain in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top